Dupilumab for the treatment of prurigo nodularis: A systematic review
BackgroundConventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.ObjectiveThe objective of this study was to systematically review dupilumab-related t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1092685/full |
| _version_ | 1828057933167984640 |
|---|---|
| author | Peng Cao Peng Cao Wenjing Xu Wenjing Xu Shuyi Jiang Shuyi Jiang Litao Zhang |
| author_facet | Peng Cao Peng Cao Wenjing Xu Wenjing Xu Shuyi Jiang Shuyi Jiang Litao Zhang |
| author_sort | Peng Cao |
| collection | DOAJ |
| description | BackgroundConventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.ObjectiveThe objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.MethodsSeveral databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.ResultsAfter 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119).ConclusionsDupilumab has definite effectiveness and safety in prurigo nodularis treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802). |
| first_indexed | 2024-04-10T21:20:00Z |
| format | Article |
| id | doaj.art-c33bc1fcba9d48a28eafb4df4ebd4f68 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T21:20:00Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c33bc1fcba9d48a28eafb4df4ebd4f682023-01-20T06:44:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011410.3389/fimmu.2023.10926851092685Dupilumab for the treatment of prurigo nodularis: A systematic reviewPeng Cao0Peng Cao1Wenjing Xu2Wenjing Xu3Shuyi Jiang4Shuyi Jiang5Litao Zhang6Graduate School, Tianjin Medical University, Tianjin, ChinaDepartment of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaDepartment of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaDepartment of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaDepartment of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaBackgroundConventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.ObjectiveThe objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.MethodsSeveral databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.ResultsAfter 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119).ConclusionsDupilumab has definite effectiveness and safety in prurigo nodularis treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).https://www.frontiersin.org/articles/10.3389/fimmu.2023.1092685/fulldupilumabbiologicsprurigo nodularisitchtreatment |
| spellingShingle | Peng Cao Peng Cao Wenjing Xu Wenjing Xu Shuyi Jiang Shuyi Jiang Litao Zhang Dupilumab for the treatment of prurigo nodularis: A systematic review Frontiers in Immunology dupilumab biologics prurigo nodularis itch treatment |
| title | Dupilumab for the treatment of prurigo nodularis: A systematic review |
| title_full | Dupilumab for the treatment of prurigo nodularis: A systematic review |
| title_fullStr | Dupilumab for the treatment of prurigo nodularis: A systematic review |
| title_full_unstemmed | Dupilumab for the treatment of prurigo nodularis: A systematic review |
| title_short | Dupilumab for the treatment of prurigo nodularis: A systematic review |
| title_sort | dupilumab for the treatment of prurigo nodularis a systematic review |
| topic | dupilumab biologics prurigo nodularis itch treatment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1092685/full |
| work_keys_str_mv | AT pengcao dupilumabforthetreatmentofprurigonodularisasystematicreview AT pengcao dupilumabforthetreatmentofprurigonodularisasystematicreview AT wenjingxu dupilumabforthetreatmentofprurigonodularisasystematicreview AT wenjingxu dupilumabforthetreatmentofprurigonodularisasystematicreview AT shuyijiang dupilumabforthetreatmentofprurigonodularisasystematicreview AT shuyijiang dupilumabforthetreatmentofprurigonodularisasystematicreview AT litaozhang dupilumabforthetreatmentofprurigonodularisasystematicreview |